Markets:

Overview

News

Currencies

International

Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

2.935 +0.065 (+2.26%)

Streaming Delayed Price Updated: 10:36 AM EDT, Jul 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

March 20, 2024

EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(OTCQX:HWAIF),(OTCQB:VRSSF),(NYSE:PATH),(NASDAQ:LTRN) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 19, 2024

Via Benzinga

LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 ↗

March 18, 2024

LTRN stock results show that Lantern Pharma beat analyst estimates for earnings per share the fourth quarter of 2023.

Via InvestorPlace

Recap: Lantern Pharma Q4 Earnings ↗

March 18, 2024

Via Benzinga

Lantern Pharma Earnings Preview ↗

March 15, 2024

Via Benzinga

Lantern Pharma: Q3 Earnings Insights ↗

November 08, 2023

Via Benzinga

A Preview Of Lantern Pharma's Earnings ↗

November 07, 2023

Via Benzinga

Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028

March 20, 2024

From FN Media Group LLC

Via GlobeNewswire

Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights

March 18, 2024

From Lantern Pharma Inc.

Via Business Wire

Earnings Scheduled For March 18, 2024 ↗

March 18, 2024

Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to report earnings for its fourth quarter.

Via Benzinga

Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284

March 15, 2024

From Lantern Pharma Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 11, 2024

Via Benzinga

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET

March 11, 2024

From Lantern Pharma Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 08, 2024

Via Benzinga

Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday ↗

March 06, 2024

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Wednesday.

Via Benzinga

Topics Stocks

Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

March 06, 2024

Shares of United Natural Foods, Inc. (NYSE: UNFI) fell sharply during Wednesday’s session following second-quarter results.

Via Benzinga

Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference

March 05, 2024

From Lantern Pharma Inc.

Via Business Wire

Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines

March 04, 2024

From Lantern Pharma Inc.

Via Business Wire

AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD ↗

March 04, 2024

Grand View Research says the global

Via Talk Markets

3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom ↗

February 20, 2024

Discover how these AI powerhouses are leveraging AI in the IT consulting, application software, and biotech industries.

Via InvestorPlace

Topics Artificial Intelligence

AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics ↗

February 19, 2024

The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway.

Via Talk Markets

Topics Artificial Intelligence

Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers

February 15, 2024

From Lantern Pharma Inc.

Via Business Wire

Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer

January 17, 2024

From Lantern Pharma

Via Business Wire

AI-Focused Drug Discovery Stocks Index Up 26% In December ↗

December 29, 2023

With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions.

Via Talk Markets

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

December 18, 2023

Via Benzinga

AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week ↗

December 17, 2023

A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method.

Via Talk Markets

Topics Artificial Intelligence

The 3 Most Undervalued AI Penny Stocks to Buy in December ↗

December 13, 2023

These AI penny stocks offer substantial returns to investors as the market continues to grow at a rapid pace.

Via InvestorPlace

Topics Artificial Intelligence

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

November 30, 2023

From Lantern Pharma Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 09, 2023

Via Benzinga

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

November 08, 2023

From Lantern Pharma Inc.

Via Business Wire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.